Replimune Group’s (REPL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Replimune Group (NASDAQ:REPL) in a report issued on Friday,Benzinga reports. They currently have a $17.00 price target on the stock.

A number of other brokerages have also recently weighed in on REPL. Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Price Performance

Shares of REPL opened at $14.93 on Friday. The stock has a market cap of $1.02 billion, a PE ratio of -4.90 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The firm’s 50-day simple moving average is $11.59 and its two-hundred day simple moving average is $9.74.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Analysts anticipate that Replimune Group will post -3.02 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently bought and sold shares of REPL. Millennium Management LLC grew its stake in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Braidwell LP grew its stake in shares of Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after buying an additional 2,057,460 shares in the last quarter. State Street Corp grew its stake in shares of Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after buying an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after buying an additional 699,679 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.